ArticleFrontiers in oncology2025
Significantly higher incidence of circulating fatty objects in portal blood samples compared to peripheral blood samples in patients with pancreatic ductal adenocarcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We previously reported the identification of circulating fatty objects (CFOs), abnormal entities found in peripheral blood samples from cancer patients. CFOs are large spherical objects with high contents of heavy cholesterol lipids, posing a risk of vessel embolization and circulation occlusion, common complications in clinical cancers. Initial characterization suggested that CFOs bear resemblance to bile salts, prompting further investigation into the potential link between bile and cancer-associated vascular occlusion. Methods: To explore this connection, we analyzed portal blood samples from patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), as CFOs were most frequently detected in this type of cancer (20.4% incidence). Portal vein samples were collected via transhepatic endoscopic ultrasound-guided fine-needle aspiration and treated with ammonium chloride hemolysis to facilitate enumeration and characterization of CFOs in the nucleated blood cell fraction. Results: CFOs were observed in 14 out of the 16 portal samples, indicating a significantly higher incidence compared to peripheral samples. Despite this, portal CFOs exhibited similar characteristics to peripheral CFOs. In a parallel study, a portion of the portal samples was filtered through an Exthera's Seraph 100 column before hemolysis, resulting in no detection of CFOs. Discussion: These findings suggest that CFOs originate from bile. It is probable that CFOs are insoluble bile lipids that have ebbed into the portal vein and subsequently shunted to the systemic circulation due to PDAC-induced hepatobiliary system abnormalities. It appears that hemofiltration can effectively remove CFOs from circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.